AMARIN CORPORATION PLC

Amarin Corporation PLC is a global pharmaceutical organisation dedicated to reshaping cardiovascular care. With its Irish arm, Amarin Pharmaceuticals Ireland Limited, the company pursues a bold vision to stop cardiovascular disease from remaining a leading cause of death worldwide. By applying cutting‑edge science, research and a strategic, financially responsible approach, Amarin develops and commercialises therapeutics that provide additional protection for patients at risk of heart disease.

The company’s flagship products – Vascepa, Vazkepa and the REDUCE‑IT programme – exemplify its focus on innovative treatments that target elevated triglycerides and broader cardiovascular risk. Amarin’s pipeline continues to explore new therapies, while its science and health platforms deliver the latest clinical insights to healthcare professionals. In addition to patients, the firm serves clinicians, investors and job‑seekers, offering transparent investor relations, career opportunities and a commitment to corporate governance.

Rooted in Ireland yet operating on a global scale, Amarin combines scientific ambition with a patient‑centred ethos, striving to make a life‑changing impact on cardiovascular health for people around the world.